Common Light Chain Antibody

Kyinno's Bispecific Antibody Platform with Common Light Chain Mice

Following the success of Akesobio and Kelun Innovations, which collectively achieved over 10 billion USD in antibody drug licensing, more good news has arrived at the beginning of the new year regarding domestic pharmaceutical companies licensing novel antibody drug molecule. Among these, Hengrui Pharmaceuticals, CSPC, and WuXi AppTec have all successfully licensed new drug molecules to overseas entities. GSK and WuXi AppTec have reached a licensing agreement. GSK will obtain exclusive rights to up to 4 TCE bispecific antibodies/multispecific antibodies developed based on WuXi AppTec’s patented technology platform. For this, GSK will pay 1.5 billion US dollars (10.1 billion RMB) and a certain sales share. WuXi AppTec’s TCE bispecific antibodies target tumor-associated antigens (TAA) present on the surface of tumor cells and CD3 antigens found on the surface of T cells. By binding to both tumor cells and T cells, these antibodies trigger specific activation of T cells, enabling them to efficiently eliminate tumor cells. The concept of bispecific antibodies (BsAbs) was first introduced by A. Nisonoff and colleagues in 1960. Based on differences in molecular structure, BsAbs can be classified into two main categories: those based on antibody fragments and those based on Fc domains. BsAbs offer a unique combination of advantages, including increased effectiveness and reduced toxicity when compared to monoclonal antibodies. Furthermore, they can mediate a range of specific biological effects, such as cell bridging, dual-target blockade, and the formation of protein complexes.
The concept of bispecific antibodies

In the year 2022, we witnessed an explosion of bispecific antibodies with a total of six BsAbs gaining regulatory approval and entering the market. This number exceeds the total for previous years. Towards the end of the year, two novel bispecific antibodies were featured in the prestigious New England Journal of Medicine. The bispecific antibody field is poised for success, with nine bispecific antibody drugs having received regulatory approval to date. Analyzing the nine approved bispecific antibodies, five maintain the natural antibody conformation, indicating a potentially higher success rate in developing these new structural drugs. Among these five, Emicizumab is a common light chain bispecific antibody, while Amivantamab and Teclistamab are based on Genmab’s duobody technology. Mosunetuzumab and Faricimab employ Genentech’s Crossmab technology. While Genmab’s duobody technology requires the development of two antibodies and their in vitro assembly, Crossmab technology is still under patent, and its development process is complex. When considering aspects like production and pharmaceutical development, the common light chain technology undoubtedly holds several advantages.
approved bispecific antibodies

To support the development of bispecific antibodies, Kyinno has successfully developed the Common Light Chain (KY-CLCTM) Mouse technology platform. The KY-CLC-mouse features no lambda (λ) light chain expression and fully identical kappa (κ) light chains, which offer excellent solubility and stability (protected by patent). KY-CLC-mouse enables rapid and efficient screening for high-affinity, highly specific antibodies against all validated targets. Bispecific antibodies assembled using this platform are comparable to monoclonal antibodies in terms of expression, purification, stability, and other critical attributes.

We welcome collaboration to explore the opportunities this platform provides.

Common Light Chain (KY-CLCTM) Mouse technology platform

Affinity tests of LAG3/PD1, PD-L1/EGFR, MET/EGFR bispecific antibodies:

Affinity tests of LAG3 PD1, PD-L1 EGFR, MET EGFR bispecific antibodies

Case Study

1. LAG3/PD1 bispecific antibody

Binding affinities of bispecific antibody KA-1833 against PD1 and LAG3 to PD1-HIS and LAG3-HIS

LAG3 PD1 bispecific antibody


2. Blocking activity of bispecific antibody KA-1833 against PD1 and LAG3

Blocking activity of bispecific antibody KA-1833 against PD1 and LAG3



4. PD1


5. LAG3


6. PDL1




7. CD47



  1. Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
  2. Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. Review – Cancer Research. 28 September 2020